Recon: AstraZeneca lines up EU accelerated assessment for COVID prevention drug; India expert panel urges local approval of Lilly’s Mounjaro

• Congress called for an ALS moonshot. The plan for it doesn’t leave Earth (STAT)
• Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry (STAT)
• Medicare should wait on approving coverage for new obesity drugs (STAT)
• Q&A: Vertex’s pain research chief on moving beyond opioids, AI and how pharma acquisitions thrive or fail (Endpoints)
• Cassava Sciences forms internal panel after US probe into two employees (Reuters)
• Rite Aid bankruptcy plan approved, cutting $2 bln in debt (Reuters)

• U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer (STAT)
• India’s Drug Regulatory Apparatus Set For ‘Big Ticket’ Changes (Pink Sheet)
• India panel urges drug regulator to approve Lilly's obesity drug Mounjaro (Reuters)
• AstraZeneca's COVID prevention drug application gets EU fast-track assessment (Reuters)
• Sanofi eyes German insulin investment of up to $1.6 bln, source says (Reuters)
• Hemophilia Gene Therapy Hemgenix Gets Funding In England, With More Talks Underway In Europe (Pink Sheet)
• EMA Seeks Input on Modernizing 17-Year-Old Psoriatic Arthritis Guide (Pink Sheet)
• EU CHMP Opinions And MAA Updates (Pink Sheet)
• Japan's Eisai developing dementia drug for US market, Nikkei reports (Reuters)
• Scientists wary of bird flu pandemic 'unfolding in slow motion' (Reuters)
• Bristol Myers to pay $2.7 mln to settle Israel anti-competition charges (Reuters)

• The maddening saga of how an Alzheimer’s ‘cabal’ thwarted progress toward a cure for decades (STAT)
• Boehringer Ingelheim enters 'triple-G' race with Phase 1 trial (Endpoints)
• Lilly inks radiopharma deal with Radionetics, with rights to buy the biotech (Endpoints)
• Aerovate plans to lay off nearly all employees after trial failure (Endpoints)
• EU regulator backs approval for ARS Pharma's nasal spray alternative to EpiPen (Reuters)
• Eisai takes over development of ADC after Bristol Myers ends $650M collaboration (Endpoints)
• UniQure sells Massachusetts manufacturing site to Genezen as it continues to downsize (Endpoints)
• Tracon to seek ‘strategic’ options; Ovid to lay off 17 workers (Endpoints)
• Dianthus teases preclinical data for autoimmune drug as it starts clinical trials (Endpoints)
• Therapy developer Alumis seeks up to $1 bln valuation in US IPO (Reuters)

• Novel amputation procedure makes walking with a prosthetic leg feel more seamless (STAT)
• Masimo COO says he’ll resign if CEO Kiani is forced out (MedTech Dive)
• Medtech M&A may pick up after mixed start to 2024: analysts (MedTech Dive)
• Philips BiPAP recall now linked to 65 deaths, 952 injuries (MedTech Dive)

• Steward Health Care spent millions on surveillance of its critics — even amid financial crisis (STAT)
• Ascension is racing to unload hospitals as execs work to stem losses (STAT)
• Medicare’s big experiment to fix kidney failure care hasn’t worked so far, studies say (STAT)
• Cancer victims lose bid to block proposed J&J talc bankruptcy (Reuters)
• US professor charged with manipulating data for Alzheimer’s drug trial (Reuters)